<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="89901">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01934712</url>
  </required_header>
  <id_info>
    <org_study_id>NN1218-3918</org_study_id>
    <secondary_id>U1111-1121-2896</secondary_id>
    <secondary_id>JapicCTI-132253</secondary_id>
    <nct_id>NCT01934712</nct_id>
  </id_info>
  <brief_title>A Trial Investigating the Pharmacokinetic Properties of FIAsp in Japanese Subjects With Type 1 Diabetes</brief_title>
  <official_title>A Trial Investigating the Pharmacokinetic Properties of FIAsp in Japanese Subjects With Type 1 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is conducted in Japan. The aim of the trial is to evaluate the pharmacokinetic
      (the exposure of the trial drug in the body) and pharmacodynamic (the effect of the trial
      drug on the body) properties of FIAsp (faster-acting insulin aspart) and the currently
      marketed insulin aspart (NovoRapid速) in Japanese subjects with type 1 diabetes.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Actual">January 2014</completion_date>
  <primary_completion_date type="Actual">January 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the serum insulin aspart concentration-time curve</measure>
    <time_frame>From 0-1 hour</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the serum insulin aspart concentration-time curve</measure>
    <time_frame>From 0-12 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the glucose infusion rate (GIR) curve</measure>
    <time_frame>From 0-1 hour</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the glucose infusion rate (GIR) curve</measure>
    <time_frame>From 0-12 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Diabetes</condition>
  <condition>Diabetes Mellitus, Type 1</condition>
  <arm_group>
    <arm_group_label>FIAsp</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each subject will be randomly allocated to one of the two treatment sequences consisting of 2 dosing visits</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NovoRapid速</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Each subject will be randomly allocated to one of the two treatment sequences consisting of 2 dosing visits</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Faster-acting insulin aspart</intervention_name>
    <description>Single dose injected subcutaneously (s.c, under the skin)</description>
    <arm_group_label>FIAsp</arm_group_label>
    <arm_group_label>NovoRapid速</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>insulin aspart</intervention_name>
    <description>Single dose injected subcutaneously (s.c, under the skin)</description>
    <arm_group_label>FIAsp</arm_group_label>
    <arm_group_label>NovoRapid速</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 1 diabetes mellitus (as diagnosed clinically) for 12 months or longer

          -  Body mass index (BMI) 18.5-28.0 kg/m^2 (both inclusive)

        Exclusion Criteria:

          -  Subject who has donated any blood or plasma in the past month or more than 500 mL
             within 3 months prior to screening

          -  Smoker (defined as a subject who is smoking at least one cigarette, cigar or pipe
             daily)

          -  Not able or willing to refrain from smoking and use of nicotine substitute products
             during the inpatient period
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Clinical Registry (GCR, 1452)</last_name>
    <role>Study Director</role>
    <affiliation>Novo Nordisk A/S</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Fukuoka</city>
        <zip>812-0025</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>http://novonordisk-trials.com</url>
    <description>Clinical Trials at Novo Nordisk</description>
  </link>
  <reference>
    <citation>Shiramoto M, Nishida T, Hansen AK, Haahr H. Higher early insulin exposure and greater early glucose-lowering effect with faster-acting insulin aspart vs insulin aspart in Japanese patients with T1D. Diabetes 2015; 64 (Suppl. 1): A249 (983-P)</citation>
  </reference>
  <verification_date>January 2017</verification_date>
  <lastchanged_date>January 16, 2017</lastchanged_date>
  <firstreceived_date>August 30, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin degludec, insulin aspart drug combination</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin Aspart</mesh_term>
    <mesh_term>Insulin, Long-Acting</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
